Cargando…
Do We Use Methylation of NFATC1 and FOS Genes As a Biomarker for Postmenopausal Osteoporosis?
Genetic and epigenetic factors have an important role during the development of osteoporosis. Receptor activator of nuclear factor-κ B (NF-κB) (RANK)/receptor activator of NF-κB ligand (RANKL) pathway is important for the bone remodeling, and NFATC1 and FOS are the downtargets of this pathway. Here,...
Autores principales: | Kalkan, R, Tosun, O |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sciendo
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009562/ https://www.ncbi.nlm.nih.gov/pubmed/33816070 http://dx.doi.org/10.2478/bjmg-2020-0021 |
Ejemplares similares
-
Identification of gene biomarkers in patients with postmenopausal osteoporosis
por: Yang, Chenggang, et al.
Publicado: (2019) -
Inhibitory Effect of Purpurogallin on Osteoclast Differentiation In Vitro through the Downregulation of c-Fos and NFATc1
por: Kim, Kiryeong, et al.
Publicado: (2018) -
BHLHE40 promotes osteoclastogenesis and abnormal bone resorption via c-Fos/NFATc1
por: Zhang, Yufeng, et al.
Publicado: (2022) -
Ginsenoside Rg2 inhibits osteoclastogenesis by downregulating the NFATc1, c-Fos, and MAPK pathways
por: Lee, Sung-Hoon, et al.
Publicado: (2023) -
Is grand multiparity a risk factor for the development of postmenopausal osteoporosis?
por: Peker, Nuri, et al.
Publicado: (2018)